SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vasomedical Inc.
VASO 0.170+9.7%Dec 5 2:48 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TradeOfTheDay who wrote (747)11/18/1997 10:33:00 AM
From: Abe Bleich  Read Replies (1) of 1605
 
You have a valid observation, however for those patients who are amenable to the treatment and have the necessary factors that make them treatable, EECP seems to me to be the way to go.
It is far safer, with no downside risk . Preferable to a chancey invasive procedure where percentages of deaths come into play.

The effective time of the treatment is said to be three to five years, at which time it can be repeated.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News